NEITHER THIS SECURITY NOR THE SECURITIES INTO WHICH THIS SECURITY IS EXERCISABLE HAVE BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE...Security Agreement • November 21st, 2016 • Spring Bank Pharmaceuticals, Inc. • Pharmaceutical preparations
Contract Type FiledNovember 21st, 2016 Company IndustryTHIS COMMON STOCK PURCHASE WARRANT (the “Warrant”) certifies that, for value received, (the “Holder”), is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set forth, including without limitation Section 3(c), at any time on or after the date that is six months and one day after the date hereof and on or prior to 5:00 p.m. (New York time) on , 2021 (the “Expiry Time”) but not thereafter, to subscribe for and purchase from Spring Bank Pharmaceuticals, Inc., a Delaware corporation (the “Company”), up to shares (the “Warrant Shares”) of Common Stock, par value $0.0001 per share, of the Company (the “Common Stock”), subject to adjustment as provided herein. The purchase price of one share of Common Stock under this Warrant shall be equal to the Exercise Price, as defined in Section 2(b).
SECURITIES PURCHASE AGREEMENTSecurities Purchase Agreement • November 21st, 2016 • Spring Bank Pharmaceuticals, Inc. • Pharmaceutical preparations • New York
Contract Type FiledNovember 21st, 2016 Company Industry JurisdictionThis SECURITIES PURCHASE AGREEMENT (this “Agreement”) is made and entered into as of November 18, 2016 by and among Spring Bank Pharmaceuticals, Inc., a Delaware corporation (the “Company”), and the Investors identified on Exhibit A attached hereto (each an “Investor” and collectively the “Investors”).
REGISTRATION RIGHTS AGREEMENTRegistration Rights Agreement • November 21st, 2016 • Spring Bank Pharmaceuticals, Inc. • Pharmaceutical preparations • New York
Contract Type FiledNovember 21st, 2016 Company Industry JurisdictionThis REGISTRATION RIGHTS AGREEMENT (this “Agreement”) is made and entered into as of November 18, 2016 by and among Spring Bank Pharmaceuticals, Inc., a Delaware corporation (the “Company”), and the “Investors” named in that certain Securities Purchase Agreement by and among the Company and the Investors (the “Purchase Agreement”). Capitalized terms used herein have the respective meanings ascribed thereto in the Purchase Agreement unless otherwise defined herein.